Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
about
Ezetimibe for primary hypercholesterolemiaStatins for the primary prevention of cardiovascular diseaseStatins for the primary prevention of cardiovascular diseaseStatins for the primary prevention of cardiovascular diseaseEzetimibe for primary hypercholesterolemiaRisk factor thresholds: their existence under scrutinyIntensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trialCommunicating risks at the population level: application of population impact numbersComparative quantification of health risks conceptual framework and methodological issues.The contribution of leading diseases and risk factors to excess losses of healthy life in Eastern Europe: burden of disease study.Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesTraditional Risk Factors for Stroke in East AsiaA century of cholesterol and coronaries: from plaques to genes to statinsThematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversyFrequency of eating and concentrations of serum cholesterol in the Norfolk population of the European prospective investigation into cancer (EPIC-Norfolk): cross sectional studyThe prevalence, awareness, treatment, and control of dyslipidemia in northeast China: a population-based cross-sectional surveyEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsThe cumulative effect of core lifestyle behaviours on the prevalence of hypertension and dyslipidemia.Should all diabetic patients be treated with a statin?Cholesterol reduction in the prevention of coronary heart disease: therapeutic rationale and guidelines. The British Hyperlipidaemia Association.Coronary heart disease risk factors in sub-Saharan Africa: studies in Tanzanian adolescents.Serum lipid and apolipoprotein distributions in Hong Kong ChineseLow levels of cardiovascular risk factors and coronary heart disease in a UK Chinese population.Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths.Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients.Adverse trends of cardiovascular risk factors among low risk populations (1983-1994)--a cohort study of workers and farmers in Guangzhou, China.Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china.Cardiovascular risk factors and disease in general practice: results of the Nijmegen Cohort Study.Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialEvidence of lifestyle modification in the management of hypercholesterolemia.Update on guidelines for management of hypercholesterolemia.Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts.Polymorphism of rs1044925 in the acyl-CoA:cholesterol acyltransferase-1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.China suboptimal health cohort study: rationale, design and baseline characteristics.Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need?Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
P2860
Q24187681-CE996945-13F8-4CD2-AD37-621305FDE7B8Q24201513-F6F1CA48-5A9C-452D-9D30-30A44CF02DFFQ24234813-35D1C870-6F2F-4138-95A2-AF3BD41037FAQ24240283-96CE82B6-71F5-449A-B33F-A4A0EA57AFA3Q24244704-99B5BC86-E1B9-454A-83AA-CA463E6AD6FFQ24527206-88548D17-34A8-4292-832D-64B714A96593Q24569666-AC309A39-934D-4B52-A1FF-EAB9A5181D47Q24651507-412847C0-0718-49D6-82DB-0A5DB5EE0FFFQ24801397-C4D062C4-513A-48BC-8202-3CF58D815AA9Q24814195-623EC69E-9AA2-4411-8DCD-EF9D02F704E2Q26853571-8CB7276A-6415-4CDD-A89E-109CB4A12BD3Q28071330-22BB2FE1-7780-45BA-951B-DE06305C5FC8Q28080618-7F861AB4-CB77-40AA-A74D-8109860999C0Q28305315-F77BF730-450D-4521-98C8-39D19A7AC272Q28365638-E9A607A7-99D4-4912-B6A8-1E77457DE251Q29247930-D4D632A6-65E8-49B0-9074-632049B24C02Q29617910-C6E1951E-66C6-49D8-A538-6F88834F8F5AQ33343699-88F4E946-236A-43A5-89B9-7A255252779EQ33610801-BD2B7EA5-3EE0-40B2-87AB-2B5450A3CB68Q33613233-06F0CC6E-E7DA-4F6B-BD15-8B22E19E6B31Q33701921-CAB847B3-2C81-4C7F-B6F5-8271737D0FF3Q33702528-12F0FEDB-4D2C-49F7-99E9-BE364C93B952Q33704725-8C652A22-6349-432F-9951-13BFCFA26039Q33729671-42D80C44-786A-4B8B-BD52-462A3821A3EBQ33972551-A3E4971C-445C-4CC7-918B-5F93C842DC4CQ34031969-9C34BD05-14B4-43B9-9553-4A3B84B12584Q34050825-A0824A21-98BE-4107-B23F-1796299A6906Q34100585-359F14A6-6E41-420F-AAD9-DF03769D4135Q34119726-1531FBDC-ABB3-4F6E-A8E1-7AB934840227Q34221355-119BE043-BA24-4F2A-BDD2-834636A16409Q34279028-E9487D5E-4BC1-491B-A1E7-64E215B46185Q34301108-CCF55975-8597-4B83-953B-6136D83DA9ABQ34314183-A0EA0743-ED9C-4E1D-B552-CA46908B57ABQ34346101-EBBD4ABB-A3FB-45F4-B15F-C669D9B36D05Q34451605-8F4D8756-ADF6-4DD2-8F71-432C23725666Q34464265-C2B59CCC-96A8-4EA0-922C-8AE7C915F4CEQ34499464-91883936-7F99-4FCC-A5CD-ED018695EE6CQ34542566-F07008EC-7AF9-41D0-9786-B2FC9754F738Q34574778-B000933D-616D-4CF2-B0A4-1DFCE557AB2AQ34601330-48C640B1-6B70-4DA1-A89E-0E85D01774CA
P2860
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@ast
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@en
type
label
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@ast
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@en
prefLabel
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@ast
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@en
P2093
P2860
P356
P1433
P1476
Serum cholesterol concentratio ...... ow cholesterol concentrations.
@en
P2093
P2860
P304
P356
10.1136/BMJ.303.6797.276
P407
P577
1991-08-01T00:00:00Z